Who's Running Pfizer's Neurontin Antitrust Defense? Judge Says Company, Counsel "Inverted" Their Roles
This article was originally published in The Pink Sheet Daily
A magistrate judge says Pfizer has failed to find a witness who knows the basis for the company's denial of off-label marketing of the anti-epileptic; direct purchasers granted class certification.
You may also be interested in...
Judge Patti Saris finds Pfizer fraudulently marketed its anti-epileptic in violation of California law and orders the company to pay Kaiser $95 million.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.